RNAimmune secures $27M in Series A financing

RNAimmune Inc., a biopharmaceutical company in Gaithersburg specializing in discovery and development of mRNA-based therapeutics and vaccines, announced Wednesday it has secured $27 million in a Series A round of financing. The company intends to use the funding to accelerate its research and development of mRNA vaccine and drug discovery focused on infectious disease, cancer, and rare diseases.